|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Das D, Arber N and Jankowski JA:
Chemoprevention of colorectal cancer. Digestion. 76:51–67. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Niitsu Y, Takayama T, Miyanishi K, Nobuoka
A, Hayashi T, Kukitsu T, Takanashi K, Ishiwatari H, Abe T, Kogawa
T, et al: Chemoprevention of colorectal cancer. Cancer Chemother
Pharmacol. 54(Suppl 1): S40–S43. 2004.PubMed/NCBI
|
|
4
|
Boghossian S and Hawash A: Chemoprevention
in colorectal cancer-where we stand and what we have learned from
twenty year's experience. Surgeon. 10:43–52. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hosono K, Endo H, Takahashi H, Sugiyama M,
Sakai E, Uchiyama T, Suzuki K, Iida H, Sakamoto Y, Yoneda K, et al:
Metformin suppresses colorectal aberrant crypt foci in a short-term
clinical trial. Cancer Prev Res (Phila). 3:1077–1083. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Takayama T, Nagashima H, Maeda M, Nojiri
S, Hirayama M, Nakano Y, Takahashi Y, Sato Y, Sekikawa H, Mori M,
et al: Randomized double-blind trial of sulindac and etodolac to
eradicate aberrant crypt foci and to prevent sporadic colorectal
polyps. Clin Cancer Res. 17:3803–3811. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Arber N, Eagle CJ, Spicak J, Rácz I, Dite
P, Hajer J, Zavoral M, Lechuga MJ, Gerletti P, Tang J, et al:
Celecoxib for the prevention of colorectal adenomatous polyps. N
Engl J Med. 355:885–895. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Grady WM and Carethers JM: Genomic and
epigenetic instability in colorectal cancer pathogenesis.
Gastroenterology. 135:1079–1099. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Vogelstein B, Fearon ER, Hamilton SR, Kern
SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM and Bos
JL: Genetic alterations during colorectal-tumor development. N Engl
J Med. 319:525–532. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Adler DG, Gostout CJ, Sorbi D, Burgart LJ,
Wang L and Harmsen WS: Endoscopic identification and quantification
of aberrant crypt foci in the human colon. Gastrointest Endosc.
56:657–662. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bird RP: Observation and quantification of
aberrant crypts in the murine colon treated with a colon
carcinogen: Preliminary findings. Cancer Lett. 37:147–151. 1987.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Moxon D, Raza M, Kenney R, Ewing R,
Arozullah A, Mason JB and Carroll RE: Relationship of aging and
tobacco use with the development of aberrant crypt foci in a
predominantly African-American population. Clin Gastroenterol
Hepatol. 3:271–278. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ohkubo H, Takahashi H, Yamada E, Sakai E,
Higurashi T, Uchiyama T, Hosono K, Endo H, Taguri M and Nakajima A:
Natural history of human aberrant crypt foci and correlation with
risk factors for colorectal cancer. Oncol Rep. 27:1475–1480.
2012.PubMed/NCBI
|
|
14
|
Pretlow TP, Barrow BJ, Ashton WS,
O'Riordan MA, Pretlow TG, Jurcisek JA and Stellato TA: Aberrant
crypts: Putative preneoplastic foci in human colonic mucosa. Cancer
Res. 51:1564–1567. 1991.PubMed/NCBI
|
|
15
|
Sakai E, Takahashi H, Kato S, Uchiyama T,
Hosono K, Endo H, Maeda S, Yoneda M, Taguri M and Nakajima A:
Investigation of the prevalence and number of aberrant crypt foci
associated with human colorectal neoplasm. Cancer Epidemiol
Biomarkers Prev. 20:1918–1924. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Seike K, Koda K, Oda K, Kosugi C, Shimizu
K, Nishimura M, Shioiri M, Takano S, Ishikura H and Miyazaki M:
Assessment of rectal aberrant crypt foci by standard chromoscopy
and its predictive value for colonic advanced neoplasms. Am J
Gastroenterol. 101:1362–1369. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shpitz B, Bomstein Y, Mekori Y, Cohen R,
Kaufman Z, Neufeld D, Galkin M and Bernheim J: Aberrant crypt foci
in human colons: Distribution and histomorphologic characteristics.
Hum Pathol. 29:469–475. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Takayama T, Katsuki S, Takahashi Y, Ohi M,
Nojiri S, Sakamaki S, Kato J, Kogawa K, Miyake H and Niitsu Y:
Aberrant crypt foci of the colon as precursors of adenoma and
cancer. N Engl J Med. 339:1277–1284. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Endo H, Hosono K, Fujisawa T, Takahashi H,
Sugiyama M, Yoneda K, Nozaki Y, Fujita K, Yoneda M, Inamori M, et
al: Involvement of JNK pathway in the promotion of the early stage
of colorectal carcinogenesis under high-fat dietary conditions.
Gut. 58:1637–1643. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Endo H, Hosono K, Uchiyama T, Sakai E,
Sugiyama M, Takahashi H, Nakajima N, Wada K, Takeda K, Nakagama H
and Nakajima A: Leptin acts as a growth factor for colorectal
tumours at stages subsequent to tumour initiation in murine colon
carcinogenesis. Gut. 60:1363–1371. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
McLellan E and Bird RP: Effect of
disulfiram on 1,2-dimethylhydrazine- and azoxymethane-induced
aberrant crypt foci. Carcinogenesis. 12:969–672. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
McLellan EA and Bird RP: Specificity study
to evaluate induction of aberrant crypts in murine colons. Cancer
Res. 48:6183–6186. 1988.PubMed/NCBI
|
|
23
|
McLellan EA, Medline A and Bird RP:
Sequential analyses of the growth and morphological characteristics
of aberrant crypt foci: Putative preneoplastic lesions. Cancer Res.
51:5270–5274. 1991.PubMed/NCBI
|
|
24
|
Moghaddam AA, Woodward M and Huxley R:
Obesity and risk of colorectal cancer: A meta-analysis of 31
studies with 70,000 events. Cancer Epidemiol Biomarkers Prev.
16:2533–2547. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Acott AA, Theus SA, Marchant-Miros KE and
Mancino AT: Association of tobacco and alcohol use with earlier
development of colorectal cancer: Should we modify screening
guidelines? Am J Surg. 196:915–918. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yuhara H, Steinmaus C, Cohen SE, Corley
DA, Tei Y and Buffler PA: Is diabetes mellitus an independent risk
factor for colon cancer and rectal cancer? Am J Gastroenterol.
106:1911–1921. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Higurashi T, Hosono K, Endo H, Takahashi
H, Iida H, Uchiyama T, Ezuka A, Uchiyama S, Yamada E, Ohkubo H, et
al: Eicosapentaenoic acid (EPA) efficacy for colorectal aberrant
crypt foci (ACF): A double-blind randomized controlled trial. BMC
Cancer. 12:4132012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mutch MG, Schoen RE, Fleshman JW,
Takahashi H, Iida H, Uchiyama T, Ezuka A, Uchiyama S, Yamada E and
Ohkubo H: A multicenter study of prevalence and risk factors for
aberrant crypt foci. Clin Gastroenterol Hepatol. 7:568–574. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Luchtenborg M, White KK, Wilkens L,
Kolonel LN and Le Marchand L: Smoking and colorectal cancer:
Different effects by type of cigarettes? Cancer Epidemiol
Biomarkers Prev. 16:1341–1347. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Stevens RG, Swede H, Heinen CD, Jablonski
M, Grupka M, Ross B, Parente M, Tirnauer JS, Giardina C, Rajan TV,
et al: Aberrant crypt foci in patients with a positive family
history of sporadic colorectal cancer. Cancer Lett. 248:262–268.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Uchiyama T, Takahashi H, Endo H, Kato S,
Sakai E, Hosono K, Yoneda M, Inamori M, Hippo Y, Nakagama H and
Nakajima A: Number of aberrant crypt foci in the rectum is a useful
surrogate marker of colorectal adenoma recurrence. Dig Endosc.
24:353–357. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Limburg PJ, Mahoney MR, Ziegler KL, Sontag
SJ, Schoen RE, Benya R, Lawson MJ, Weinberg DS, Stoffel E, Chiorean
M, et al: Randomized phase II trial of sulindac, atorvastatin and
prebiotic dietary fiber for colorectal cancer chemoprevention.
Cancer Prev Res. 4:259–269. 2011. View Article : Google Scholar
|
|
33
|
Cho NL, Redston M, Zauber AG, Carothers
AM, Hornick J, Wilton A, Sontag S, Nishioka N, Giardiello FM,
Saltzman JR, et al: Aberrant crypt foci in the adenoma prevention
with celecoxib trial. Cancer Prev Res (phila). 1:21–31. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Larsson SC, Orsini N and Wolk A: Diabetes
mellitus and risk of colorectal cancer: A meta-analysis. J Natl
Cancer Inst. 97:1679–1687. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Deng L, Gui Z, Zhao L, Wang J and Shen L:
Diabetes mellitus and the incidence of colorectal cancer: An
updated systematic review and meta-analysis. Dig Dis Sci.
57:1576–1585. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Giovannucci E: Insulin, insulin-like
growth factors and colon cancer: A review of the evidence. J Nutr.
131(Suppl 11): S3109–S3120. 2001.
|
|
37
|
Smith AJ, Stern HS, Penner M, Hay K, Mitri
A, Bapat BV and Gallinger S: Somatic APC and K-ras codon 12
mutations in aberrant crypt foci from human colons. Cancer Res.
54:5527–5530. 1994.PubMed/NCBI
|
|
38
|
Takayama T, Ohi M, Hayashi T, Miyanishi K,
Nobuoka A, Nakajima T, Satoh T, Takimoto R, Kato J, Sakamaki S and
Niitsu Y: Analysis of K-ras, APC and beta-catenin in aberrant crypt
foci in sporadic adenoma, cancer and familial adenomatous
polyposis. Gastroenterology. 121:599–611. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Siu IM, Pretlow TG, Amini SB and Pretlow
TP: Identification of dysplasia in human colonic aberrant crypt
foci. Am J Pathol. 150:1805–1813. 1997.PubMed/NCBI
|
|
40
|
Hurlstone DP and Cross SS: Role of
aberrant crypt foci detected using high-magnification-chromoscopic
colonoscopy in human colorectal carcinogenesis. J Gastroenterol
Hepatol. 20:173–181. 2005. View Article : Google Scholar : PubMed/NCBI
|
